ClinicalTrials.gg
Drug

Rifaximin clinical trials

studies test it
150
open now
23
in phase 3
39
first study started
2003

How each study uses Rifaximin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Rifaximin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
25 May 2004 · XIFAXAN · NDA 021361 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Rifaximin
103
Xifaxan
44
Rifaximin 550 MG
7
Normix
6
Rifaximin (drug)
5

Development codes

NDA 22-554
1

Other names

L-105
1

In one entry with another drug

Given together, or one or the other

Rifaximin plus lactulose
2

Studies by the year they started

150 studies that test it; most in 2013 (16)

Studies that test Rifaximin, by start year
YearStudies
20032
20041
20056
20062
20078
20085
20093
20103
20114
20128
201316
20147
201510
201610
20176
201810
201911
20206
20215
20223
20234
20248
20255
20267

By phase

A phase 1/2 study counts in both.

Early Phase 1
5
Phase 1
12
Phase 2
44
Phase 3
39
Phase 4
35
No phase
30

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 20 · Other 130

Bausch Health Americas, Inc. (16) · Institute of Liver and Biliary Sciences, India (6) · Mayo Clinic (5) · Shanghai Changzheng Hospital (4) · Shanghai Zhongshan Hospital (4) · University of Michigan (3) · Emory University (3) · Cedars-Sinai Medical Center (3)

Often tested with

Tested in the same studies.

Lactulose (11) · Probiotic (2) · Ciprofloxacin (2) · Simvastatin (2) · Glipizide (1) · Neomycin (1) · Ornithylaspartate (1) · Bromocriptine (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Rifaximin is the comparator. A study of two new drugs counts under both.

  • 1Nitazoxanide · Tanta University · next primary completion Nov 2028
Reaching primary completion within a year · 4

Studies that test Rifaximin.

Studies

Open first, then newest update. How each study uses Rifaximin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 150

See all 150 studies that test Rifaximin →

Given beside what is tested · 6 — Rifaximin is usual care or a partner of the new treatment
As the comparator · 12 — what is tested is compared with Rifaximin

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call Rifaximin · ClinicalTrials.gg INT006823

  • MeSH (NLM) D000078262RifaximinConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) L36O5T016NRIFAXIMINConfirmed FDA, NLM, Wikidata
  • RxNorm 35619Confirmed FDA, Wikidata
  • Wikidata Q416073rifaximinConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C61926RifaximinOne source FDA
  • DrugBank DB01220One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.